Lifeline Biotechnologies, Inc. Finalizes Agreement For Development of Its First Warning System(TM)
RENO, Nev.--(BUSINESS WIRE)-- Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) today announced that it has finalized and executed the Agreement for the, what is anticipated to be, final stage development of its interpretive system, a system designed to assist in the early detection of breast cancer.
Jim Holmes, Lifeline’s CEO, stated “the terms of the Agreement have been finalized and I have executed and sent it to the University in Singapore. I await the return executed Agreement. We have worked with the engineers at the University for over two years in the preliminary analysis of the patient data which we obtained from our patient testing in Argentina. The initial results from this preliminary patient analysis, indicates that the system holds capabilities of identifying breast cancer at a very early stage and at acceptable false positive and false negative levels. Now that the Agreement terms are final we will send the additional Argentina patient data for the engineers to analyze and the final development of our First Warning™ interpretive system.”
About Lifeline Biotechnologies, Inc.
The Company will focus on completing the development of the First Warning System™, designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System™ is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. Additionally, the First Warning System™ could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually. Upon successful completion of the development of the First Warning System™, conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline will commence marketing its breast cancer early detection system More information is available at the Company’s website: www.lbtn.com.
IP: Logged |
posted
Lifeline Biotechnologies, Inc. Expects to Upgrade Capabilities of Its First Warning System(TM) in 2008
Jan 2, 2008 08:31:01 (ET)
RENO, Nev., Jan 02, 2008 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (OTCPK:LLBT) today announced the Company expects to make meaningful progress in the upgrading of its First Warning System(TM) (FWS) computer software analytical and interpretive system (CSAIS). Lifeline has set specifications for the engineers at Nanyang Technical University (NTU) to upgrade the software so it is more sensitive.
The CSAIS, based on neural net technology, categorizes patient data into one of three classifications: normal, suspicious and abnormal physiology which could indicate the presence of breast cancer. As previously reported, the engineers at NTU are focused on processing the patient data recently provided to them by the Company in order to increase the software's ability to recognize and categorize patient data into these three classifications.
"The CSAIS is a neural net technology, trained to identify cancer. We have set specifications for the NTU engineers, and the recent reports from our engineers indicate that we are making meaningful progress toward meeting these specifications and look forward to the prospect of potentially accomplishing them in 2008," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.
Lifeline recently announced that the Company has been in discussions with various firms to prepare filing the 510(k) with the FDA. The selected firm will help with the verification and validation guidelines, and the Company expects to announce its selection soon.
About Lifeline Biotechnologies, Inc:
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System(TM), which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System(TM), the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. Additional information is at the Company's website: www.lbti.com . The website is being updated.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. Investor Relations, 1-886-THE APPL(E)
posted
Lifeline Biotechnologies, Inc. Continues Merger and Acquisition Prospecting
Jan 28, 2008 09:07:01 (ET)
RENO, Nev., Jan 28, 2008 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (OTCPK:LLBT) announced today that Management continues their search for industry related prospects for a prospective strategic alliance.
"We're seeking to develop a strategic alliance with opportunities that are related to early breast cancer detection. We have focused on companies that have products similar and complementary to Lifeline's First Warning System. The concentration is with opportunities that are revenue or near revenue producing. We have had discussions with several of such prospects. There is no assurance that any conclusion or relationships will develop, but there is encouragement," said Jim Holmes, Lifeline's CEO.
Meanwhile, Lifeline is focused on completing the development of the First Warning System(TM), designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System(TM) is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. The First Warning System(TM) could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion.
Lifeline Biotechnologies is in the process of securing FDA clearance, via a 510(k) for its First Warning System, and will continue to update its shareholders regarding its progress on a regular basis. To find out more information about Lifeline Biotechnologies, Inc., please visit: www.lbti.com .
About Lifeline Biotechnologies, Inc:
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System(TM), which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System(TM), the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: Lifeline Biotechnologies, Inc.
for Lifeline Biotechnologies, Inc. Investor Relations, 1-886-THE APPL(E)
posted
Lifeline Biotechnologies, Inc. CEO Reveals New Information in Audio Interview on Stockbully.com
Apr 29, 2008 08:30:06 (ET)
RENO, Nev., Apr 29, 2008 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (OTCPK:LLBT), a developer of innovative medical technology, today announced that CEO, Jim Holmes, was interviewed on www.stockbully.com . In the interview, Mr. Holmes discussed the current status of the Company's patented First Warning System(TM), a technology that could assist in the early, non-invasive detection of breast cancer.
Stockbully.com gives attention to emerging growth companies that seek more exposure in the investment community. Stockbully.com is a multimedia investor relation's source that seeks out promising and mostly undiscovered companies in the market place and enables their clients to utilize multimedia marketing to gain exposure via the information highway.
"Throughout our extensive testing, we have accomplished significant improvements in detection percentages over that of mammograms. The First Warning System(TM) is currently going through additional adjustments, at the same time we have a very promising process that could change the face of breast cancer detection," stated Lifeline Biotechnologies, Inc. President and CEO Jim Holmes. "Please visit our website ( www.lbti.com ) to stay updated on all of the recent events regarding our First Warning System(TM)."
About Stockbully.com
Stockbully.com differentiates itself from traditional investor relations businesses, in that it strives to take a long-term approach. It nurtures and supports promising emerging companies with the aim of growing and appreciating in value. Through exposure on the Internet, Stockbully.com enables its clients to secure a place in their respective sector. Clients with limited financial means can utilize multimedia marketing via the Internet to gain a competitive edge. For more information, please visit http://www.stockbully.com/ .
About Lifeline Biotechnologies, Inc:
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System(TM), which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: development of the First Warning System(TM)'s interpretive, proprietary software, clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company's product and regulatory and shareholder approval for anticipated actions.
SOURCE: Lifeline Biotechnologies, Inc.
for Lifeline Biotechnologies, Inc. e-media Direct, Inc. Investor Relations, 866-284-2835 info*e-mediadirect.com
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Frown]](frown.gif)
